» Articles » PMID: 23340442

Collagen Binding Provides a Sensitive Screen for Variant Von Willebrand Disease

Overview
Journal Clin Chem
Specialty Biochemistry
Date 2013 Jan 24
PMID 23340442
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: von Willebrand factor (VWF) is a multimeric protein that binds platelets and collagen, facilitating hemostasis at sites of vessel injury. Measurement of VWF multimer distribution is critical for diagnosis of variant von Willebrand disease (VWD), particularly types 2A and 2B, but the typical measurement by gel electrophoresis is technically difficult and time-consuming. A comparison of VWF collagen binding (VWF:CB) and VWF multimer distribution was performed to evaluate the utility of VWF:CB as a diagnostic test.

Methods: Participants were enrolled in the Zimmerman Program for the Molecular and Clinical Biology of VWD. VWF:CB was analyzed with type III collagen and multimer distribution by agarose gel electrophoresis. The study population included 146 healthy controls, 351 individuals with type 1 VWD, and 77 with type 2 VWD. Differences between individuals with multimer group results within (controls) and outside the reference intervals were assessed with Mann-Whitney tests.

Results: The mean VWF:CB/VWF antigen ratio was 1.10 for individuals with multimer distribution within the reference intervals and 0.51 for those with multimer distribution outside the reference intervals (P < 0.001). Sensitivity of VWF:CB for multimer abnormalities was 100% for healthy controls, 99% for patients with type 1, and 100% for patients with type 2A and type 2B VWD using a VWF:CB/VWF antigen cutoff ratio of 0.6, and decreased to 99% for all patients with a ratio of 0.7. With the exception of individuals with novel or unclassified mutations, the VWF:CB was able to correctly categorize participants with variant VWD.

Conclusions: These findings suggest that VWF:CB may substitute for multimer distribution in initial VWD testing, although further studies are needed to validate the clinical utility of VWF:CB.

Citing Articles

Preservation of von Willebrand Factor Activity With the ModulHeart Device.

Georges G, Trudeau F, Potvin J, Potus F, Martineau S, Genereux P JACC Basic Transl Sci. 2024; 9(1):33-42.

PMID: 38362340 PMC: 10864901. DOI: 10.1016/j.jacbts.2023.07.005.


Subunit Flexibility of Multimeric von Willebrand Factor/Factor VIII Complexes.

Parker E, Haberichter S, Lollar P ACS Omega. 2022; 7(35):31183-31196.

PMID: 36092565 PMC: 9453814. DOI: 10.1021/acsomega.2c03389.


Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease.

Boender J, Atiq F, Cnossen M, van der Bom J, Fijnvandraat K, de Meris J Hemasphere. 2021; 5(3):e542.

PMID: 33623884 PMC: 7892298. DOI: 10.1097/HS9.0000000000000542.


ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.

James P, Connell N, Ameer B, Di Paola J, Eikenboom J, Giraud N Blood Adv. 2021; 5(1):280-300.

PMID: 33570651 PMC: 7805340. DOI: 10.1182/bloodadvances.2020003265.


Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding.

Atiq F, Wuijster E, de Maat M, Kruip M, Cnossen M, Leebeek F J Thromb Haemost. 2020; 19(3):719-731.

PMID: 33370487 PMC: 7986755. DOI: 10.1111/jth.15227.


References
1.
Favaloro E, Bonar R, Chapman K, Meiring M, Funk Adcock D . Differential sensitivity of von Willebrand factor (VWF) 'activity' assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. J Thromb Haemost. 2012; 10(6):1043-54. DOI: 10.1111/j.1538-7836.2012.04729.x. View

2.
Ruggeri Z, ZIMMERMAN T . Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest. 1980; 65(6):1318-25. PMC: 371469. DOI: 10.1172/JCI109795. View

3.
Castaman G, Eikenboom J, Rodeghiero F, Briet E, Reitsma P . A novel candidate mutation (Arg611-->His) in type I 'platelet discordant' von Willebrand's disease with desmopressin-induced thrombocytopenia. Br J Haematol. 1995; 89(3):656-8. DOI: 10.1111/j.1365-2141.1995.tb08383.x. View

4.
Favaloro E . An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost. 2008; 33(8):727-44. DOI: 10.1055/s-2007-1000364. View

5.
Hubbard A, Hamill M, Beeharry M, Bevan S, Heath A . Value assignment of the WHO 6th International Standard for blood coagulation factor VIII and von Willebrand factor in plasma (07/316). J Thromb Haemost. 2011; 9(10):2100-2. DOI: 10.1111/j.1538-7836.2011.04471.x. View